Investigating the effects of antibodies when starting HIV treatment
Official title: Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation
Funded at University of Pennsylvania · NIH-10909359 · Data updated 2026-11-12
This study is looking at how using special antibodies might help people with HIV start their treatment more effectively, aiming to find better ways to manage the virus and improve health outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 17, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $825,084 |
| NIH project number | 5R01AI179666-02 |
| Project ID | NIH-10909359 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are about to start antiretroviral therapy or those who may need to re-initiate treatment after interruption.
✕Less likely to help
Patients who are not living with HIV or those who are already on stable antiretroviral therapy may not benefit from this research.
What this research studies
This research focuses on the initiation of antiretroviral therapy (ART) for individuals living with HIV, particularly examining how the infusion of broadly neutralizing antibodies (bnAbs) can impact treatment outcomes. By utilizing a specialized model that mimics the complexities of HIV infection, the study aims to understand the mechanisms behind the effectiveness of these antibodies at the start of ART. The research will explore how these antibodies can influence immune responses and virus control, potentially leading to improved treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV treatment options that enhance immune responses and control the virus more effectively.
How similar studies have gone: Previous research has shown promising results with the use of broadly neutralizing antibodies in HIV treatment, indicating potential for success in this approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Bar, Katharine June — University of Pennsylvania
- Study coordinator: Bar, Katharine June
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.